Vaccinex's book value per share for the quarter that ended in Mar. 2024 was $0.90.
During the past 12 months, Vaccinex's average Book Value Per Share Growth Rate was -90.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 78.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Vaccinex was 78.20% per year. The lowest was 50.30% per year. And the median was 58.20% per year.
Vaccinex's current price is $7.2494. Its book value per share for the quarter that ended in Mar. 2024 was $0.90. Hence, today's PB Ratio of Vaccinex is 8.09.
During the past 8 years, the highest P/B Ratio of Vaccinex was 101.89. The lowest was 1.87. And the median was 4.65.
Vaccinex Book Value per Share Historical Data
The historical data trend for Vaccinex's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vaccinex's Book Value per Share
For the Biotechnology subindustry, Vaccinex's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaccinex's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaccinex's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vaccinex's PB Ratio falls into.
Vaccinex Book Value per Share Calculation
Vaccinex's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Vaccinex (NAS:VCNX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Vaccinex Book Value per Share Related Terms
Thank you for viewing the detailed overview of Vaccinex's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCNX has been successfully added to your 